Abstract
Our previous "J-BENEFIT (Japan BEzafibrate cliNical EFfectIveness and Tolerability)" study demonstrated that bezafibrate improves blood lipid profiles and glucose control in dyslipidemic patients with diabetes. However, bezafibrate did not significantly improve low-density lipoprotein cholesterol (LDL-C), although some patients showed decreases while others showed increases in the LDL-C levels. Therefore, a subgroup analysis of the J-BENEFIT study was conducted to identify factors influencing the bezafibrate-induced changes in the LDL-C levels. Of the 3,316 patients in the J-BENEFIT study, 2,116 not treated with other lipid-lowering drugs were enrolled in the current study, and the effects of 24-week treatment with bezafibrate on the LDL-C levels were analyzed. A reduction in the LDL-C level of ≥ 25% occurred in 253 patients, and a logistic-regression analysis was used to identify factors associated with this improvement. Among the 2,116 overall patients, bezafibrate treatment significantly increased the LDL-C levels from 123.9±36.7 to 125.7±31.3 mg/dL. The subanalysis showed that the treatment responses varied according to the baseline LDL-C level, with significant decreases in the ≥ 160 and ≥ 140-<160 mg/dL groups, no signifi...Continue Reading
References
Jul 1, 1990·Circulation·M I UusitupaK Pyörälä
Aug 3, 2001·Archives of Internal Medicine·Y CuiT L Bush
Jun 28, 2001·Journal of Atherosclerosis and Thrombosis·T NagaiM Mori
Oct 31, 2001·Cardiovascular Research·J MalikJ Hradec
May 9, 2002·Atherosclerosis·Juan A Gómez-GeriqueUNKNOWN ATOMIX Investigators
May 29, 2002·Diabetes Care·Ernst J SchaeferUNKNOWN Framingham Offspring Study
Oct 3, 2002·Circulation·Akihiko WakatsukiTakao Fukaya
Jan 17, 2004·Arteriosclerosis, Thrombosis, and Vascular Biology·Tsutomu HiranoGen Yoshino
May 24, 2005·International Journal of Cardiology·Katsunori IkewakiSeibu Mochizuki
Jun 9, 2005·Journal of Atherosclerosis and Thrombosis·Hidenori AraiToru Kita
Oct 11, 2005·Lancet·C BaigentUNKNOWN Cholesterol Treatment Trialists' (CTT) Collaborators
Dec 1, 2005·Circulation·Tobias PischonEric B Rimm
Jan 16, 2007·Atherosclerosis·Yasushi SaitoJonathan C Fox
Mar 24, 2007·Clinical and Experimental Medicine·H A KhanS A Khan
Jan 15, 2008·Lancet·P M KearneyC Baigent
Nov 22, 2008·Journal of the American College of Cardiology·Edward J MillsDan Perri
Jul 2, 2009·BMJ : British Medical Journal·J J BrugtsJ W Deckers
Jul 9, 2009·Diabetes/metabolism Research and Reviews·L ZhangZ C Pang
Jun 25, 2010·Circulation Journal : Official Journal of the Japanese Circulation Society·Keita SanoKiyotaka Kugiyama
Nov 12, 2010·Lancet·UNKNOWN Cholesterol Treatment Trialists’ (CTT) CollaborationR Collins
Mar 8, 2011·Journal of Atherosclerosis and Thrombosis·Akihiko KitamuraHiroyasu Iso
Aug 26, 2011·The Journal of Clinical Endocrinology and Metabolism·Hirohito SoneUNKNOWN Japan Diabetes Complications Study Group
Sep 16, 2011·The Annals of Pharmacotherapy·Kandace L AmendAndrew McAfee
Feb 18, 2012·Diabetes Care·Hirohito SoneUNKNOWN Japan Diabetes Complications Study Group
Mar 24, 2012·Cardiovascular Diabetology·Tamio TeramotoNobuhiro Yamada
Apr 24, 2012·PloS One·Alexander TenenbaumIlan Goldenberg
Oct 26, 2013·The American Journal of Cardiology·Robert KlempfnerAlexander Tenenbaum
Nov 8, 2013·Cardiovascular Diabetology·Tamio TeramotoTakehiko Taneyama
Apr 9, 2014·Cardiovascular Diabetology·Yuko OhnoHiroshi Ito
Citations
Jan 15, 2017·Cardiovascular Diabetology·Toshiyuki HayashiTsutomu Hirano
Oct 18, 2018·Expert Review of Clinical Pharmacology·Bogusław OkopieńAleksandra Bołdys
Jun 23, 2018·Frontiers in Endocrinology·Yezi ZouHeqing Huang
Mar 11, 2015·Journal of Atherosclerosis and Thrombosis·Junji Kobayashi
Feb 22, 2021·Lipids in Health and Disease·Ichiro KomiyaTamio Wakugami